Faculty Profiles - KANDA Mitsuro

Papers - KANDA Mitsuro

Division display 41 - 60 of about 573 ／ All the affair displays >>

Risk Stratification by Tissue<i> GAD1</i> Expression Level in Curatively Resected Esophageal Squamous Cell Carcinoma Reviewed

Kishida, T; Kanda, M; Sato, Y; Shimizu, D; Inokawa, Y; Hattori, N; Hayashi, M; Tanaka, C; Nakayama, G; Kodera, Y

CANCER GENOMICS & PROTEOMICS Vol. 20 ( 6 ) page： 617 - 625 2023.11

Real clinical impact of postoperative surgical complications after colon cancer surgery Reviewed

Aoyama, T; Oba, K; Honda, M; Mayanagi, S; Maeda, H; Kanda, M; Kashiwabara, K; Muto, M; Sakamoto, J; Yoshikawa, T

ANNALS OF ONCOLOGY Vol. 34 page： S1509 - S1509 2023.11

Predictive impacts of peritoneal washing cytology for surgical resection-intended pancreatic cancer cases: Establishment of planned staging laparoscopy criteria Reviewed

Tanaka, N; Takami, H; Hayashi, M; Inokawa, Y; Kurimoto, K; Hattori, N; Kanda, M; Tanaka, C; Nakayama, G; Kodera, Y

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES Vol. 30 ( 11 ) page： 1273 - 1281 2023.11

Mobilization of Circulating Tumor Cells after Short- and Long-Term FOLFIRINOX and GEM/nab-PTX Chemotherapy in Xenograft Mouse Models of Human Pancreatic Cancer Reviewed

Ito, Y; Kobuchi, S; Kawakita, A; Tosaka, K; Matsunaga, Y; Yoshioka, S; Jonan, S; Amagase, K; Hashimoto, K; Kanda, M; Saito, T; Nakanishi, H

CANCERS Vol. 15 ( 22 ) 2023.11

Low Expectancy of Conversion Surgery with R0 Resection in Patients with CEA > 5.0 ng/mL at the Initial RECIST Evaluation for Metastatic Gastric Cancer Reviewed

Koki Nakanishi, Chie Tanaka, Mitsuro Kanda, Kazushi Miyata, Kazuhiro Furukawa, Osamu Maeda, Dai Shimizu, Shizuki Sugita, Naomi Kakushima, Satoshi Furune, Hiroki Kawashima, Yuichi Ando, Tomoki Ebata, Yasuhiro Kodera

Cancers Vol. 15 ( 21 ) 2023.11

進行再発大腸癌に対するFOLFIRI(irinotecan日本標準量:150mg/m2)+ramucirumab療法 Reviewed

服部憲史, 中山吾郎, 室谷健太, 梅田晋一, 川瀬義久, 江坂和大, 筒山将之, 阪井満, 片岡政人, 伊藤武, 神田光郎, 田中千恵, 藤原道隆, 安藤昌彦, 小寺泰弘

日本癌治療学会学術集会抄録集 Vol. 61回 page： O16 - 1 2023.10

進行再発大腸癌に対するFOLFIRI(irinotecan日本標準量:150mg/m2)+ramucirumab療法 Reviewed

日本癌治療学会学術集会抄録集 Vol. 61回 page： O16 - 1 2023.10

Identification of stromal cell-derived factor 4 as a liquid biopsy-based diagnostic marker in solid cancers Reviewed

Shinozuka, T; Kanda, M; Shimizu, D; Umeda, S; Takami, H; Inokawa, Y; Hattori, N; Hayashi, M; Tanaka, C; Nakayama, G; Kodera, Y

SCIENTIFIC REPORTS Vol. 13 ( 1 ) page： 15540 2023.9

Site-specific protein biomarkers in gastric cancer: a comprehensive review of novel biomarkers and clinical applications Reviewed

Shinozuka Takahiro, Kanda Mitsuro, Kodera Yasuhiro

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS Vol. 23 ( 8 ) page： 701 - 712 2023.8

The preoperative systemic immune-inflammation index is associated with an unfavorable prognosis for patients undergoing curative resection of esophageal squamous cell carcinoma after neoadjuvant therapy Reviewed

Obata Yuma, Kanda Mitsuro, Shimizu Dai, Takami Hideki, Inokawa Yoshikuni, Hattori Norifumi, Hayashi Masamichi, Tanaka Chie, Nakayama Goro, Kodera Yasuhiro

SURGERY TODAY Vol. 53 ( 8 ) page： 964 - 972 2023.8

A feasibility study of modified docetaxel, cisplatin, and capecitabine for advanced gastric cancer followed by gastrectomy. Reviewed International journal

Yao Liang, Osamu Maeda, Kazushi Miyata, Chie Tanaka, Mitsuro Kanda, Dai Shimizu, Masahide Fukaya, Masahiko Koike, Yasuhiro Kodera, Yuichi Ando

Asia-Pacific journal of clinical oncology 2023.7

Language：English Publishing type：Research paper (scientific journal)

AIMS: To explore the feasibility of modified docetaxel, cisplatin, and capecitabine (mDCX) chemotherapy with a lower dose of docetaxel than previously reported for stage III resectable gastric cancer patients with a high risk of recurrence or for stage IV gastric cancer patients aiming for conversion surgery. METHODS: Patients with stage III resectable HER2-negative gastric cancer with large type 3 or type 4 tumors or extensive lymph node metastasis (bulky N or cN3) and those who had stage IV HER2-negative gastric cancer with distant metastasis were enrolled to receive 30 mg/m2 docetaxel and 60 mg/m2 cisplatin on day 1, followed by 2000 mg/m2 capecitabine per day for 2 weeks every 3 weeks. RESULTS: Five patients with stage III gastric cancer with a high risk of recurrence received three courses of mDCX, and four patients with stage IV gastric cancer received three or four courses of mDCX. In terms of grade 3 or worse adverse events, leukopenia was observed in one (11%) patient, neutropenia in two (22%) patients, anemia in one (11%) patient, anorexia in two (22%) patients and nausea in two (22%) patients. All six patients with measurable lesions achieved a partial response. All nine patients underwent subsequent surgeries. The histological responses of the nine patients revealed grade 3 in one (11%) patient, grade 2 in five (56%) patients, and grade 1a in three (33%) patients. Three of the nine patients survived without recurrence, and two of them survived for more than four years. CONCLUSIONS: mDCX seems to be feasible and may be helpful as neoadjuvant chemotherapy for patients at high risk of recurrence or as chemotherapy for patients who are likely to undergo conversion surgery.

DOI： 10.1111/ajco.13995

Web of Science

PubMed

High Preoperative Serum D-dimer Predicts Unfavorable Survival Outcomes for Pancreatic Cancer Patients. Reviewed International journal

Tomohisa Otsu, Masamichi Hayashi, Hideki Takami, Yoshikuni Inokawa, Nobutake Tanaka, Keisuke Kurimoto, Koki Nakanishi, Shinichi Umeda, Dai Shimizu, Norifumi Hattori, Mitsuro Kanda, Chie Tanaka, Goro Nakayama, Yasuhiro Kodera

Anticancer research Vol. 43 ( 7 ) page： 3173 - 3181 2023.7

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND/AIM: Pancreatic cancer cells release certain tissue factors into the bloodstream. It is well known that pancreatic cancer progresses with thrombus formation. Because we routinely measure serum D-dimer levels in preoperative patients as a screening marker of deep venous thrombosis, we examined its association with high serum D-dimer in our cohort of pancreatic cancer resected cases. PATIENTS AND METHODS: We examined 315 patients with pancreatic ductal adenocarcinoma who underwent surgical resection in our department from January 2012 to July 2021. All cases were divided into high D-dimer cases (n=118) and low D-dimer cases (n=197) using the cut-off value of 1.0 μg/ml, an institutional upper limit. Clinicohistological characteristics and postoperative survival outcomes were evaluated. RESULTS: Preoperative high D-dimer cases showed significantly worse progression-free survival (PFS) (p=0.021) and overall survival (OS) (p=0.027) than low D-dimer cases; median PFS was 13.9 months versus 21.4 months, and that of OS was 33.4 months versus 68.0 months. Clinicohistological characteristics of high D-dimer cases were age over 70 years (p<0.001), pathological portal vein invasion (p=0.003), and initially borderline resectable or unresectable cases (p=0.027). Multivariate analysis indicated that preoperative high D-dimer was a significant prognostic factor of PFS (hazard ratio=1.42, p=0.025) and OS (hazard ratio=1.51, p=0.036). CONCLUSION: Preoperative high serum D-dimer over 1.0 μg/ml was associated with pathological portal vein invasion and could be an unfavorable prognostic marker of PFS and OS after surgery, typically due to distant metastasis.

DOI： 10.21873/anticanres.16491

PubMed

Feasibility and Safety of Adjuvant Chemotherapy for Resected Colorectal Cancer in Patients With Renal Insufficiency: A Pooled Analysis of Individual Patient Data from Five Japanese Large-scale Clinical Trials. Reviewed International journal

Shuhei Mayanagi, Koji Oba, Toru Aoyama, Kenji Tanaka, Mitsuro Kanda, Michitaka Honda, Hiromichi Maeda, Kosuke Kashiwabara, Masaru Muto, Junichi Sakamoto, Hisakazu Yamagishi, Takaki Yoshikawa

Anticancer research Vol. 43 ( 7 ) page： 3089 - 3095 2023.7

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND/AIM: The incidence of chemotherapy-related adverse events in colorectal cancer patients with renal insufficiency has been compared to patients with normal renal function in only a few studies. The purpose of this analysis was to verify the feasibility and safety of adjuvant chemotherapy for postoperative colorectal cancer patients with renal insufficiency. PATIENTS AND METHODS: Adverse events and discontinuation of adjuvant chemotherapy for patients with curatively resected locally advanced colorectal cancer were examined using a combined database of individual patient data obtained from five large-scale clinical trials (n=4,106). The renal function of patients was classified into Level (L) 1-2: ≥60 ml/min and L3-4: <60 ml/min. RESULTS: As Grade 3 adverse events, hematological toxicities, such as neutropenia and anemia, and gastrointestinal disorders, such as diarrhea and vomiting, were significantly more frequent in the L3-4 group. Moreover, the time-to-treatment discontinuation in the L3-4 group was higher (hazard ratio=1.21, p=0.0012). T factor, N factor, and creatinine clearance level were found to be independent risk factors for the discontinuation of adjuvant chemotherapy. In the subgroup analysis of FOLFOX, neutropenia and diarrhea were significantly common in the L3-4 group, but neurotoxicities were not different. There was no significant difference in the discontinuation of adjuvant FOLFOX. CONCLUSION: Adverse events of adjuvant chemotherapy in patients with resected colorectal cancer were associated with renal insufficiencies. Since adverse events have the potential to shorten the duration of treatment, especially when using chemotherapy without oxaliplatin, careful management, including dose reduction, may be important in patients with renal insufficiency.

DOI： 10.21873/anticanres.16480

PubMed

High Preoperative Platelet to Lymphocyte Ratio is Associated with a Greater Risk of Postoperative Complications and Hematogenous Recurrences in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Treatment Reviewed

Sasahara Masahiro, Kanda Mitsuro, Shimizu Dai, Takami Hideki, Inokawa Yoshikuni, Hattori Norifumi, Hayashi Masamichi, Tanaka Chie, Fujiwara Michitaka, Nakayama Goro, Kodera Yasuhiro

DIGESTIVE SURGERY Vol. 40 ( 1-2 ) page： 48 - 57 2023.7

食道扁平上皮癌における術前凝固状態と術後再発の関連性 Reviewed

杉山史剛, 神田光郎, 清水大, 田中千恵, 中西香企, 服部憲史, 林真路, 中山吾郎, 藤原道隆, 小寺泰弘

日本消化器外科学会総会 Vol. 78回 page： P217 - 2 2023.7

腹腔鏡下切除術を施行した食道重複嚢胞の一例 Reviewed

武田洋平, 清水大, 中西香企, 高見秀樹, 猪川祥邦, 服部憲史, 林真路, 神田光郎, 田中千恵, 中山吾郎, 藤原道隆, 小寺泰弘

日本臨床外科学会雑誌 Vol. 84 ( 7 ) page： 1129 - 1129 2023.7

胸骨後経路再建による食道亜全摘術後縫合不全と胸郭入口部気管食道間角度・胸骨椎骨間距離長の関連性の検討 Reviewed

呂成九, 神田光郎, 清水大, 田中千恵, 中西香企, 服部憲史, 林真路, 中山吾郎, 藤原道隆, 小寺泰弘

日本消化器外科学会総会 Vol. 78回 page： P206 - 2 2023.7

【上部】【Challenges beyond borders】高度進行胃癌に対するconversion surgeryの現状と新たな治療戦略高齢者における治癒切除不能胃癌に対するconversion surgeryの治療成績 Reviewed

中西香企, 田中千恵, 神田光郎, 宮田一志, 清水大, 杉田静紀, 藤原道隆, 江畑智希, 小寺泰弘

日本消化器外科学会総会 Vol. 78回 page： PD3 - 9 2023.7

The clinical impacts of postoperative complications after colon cancer surgery for the clinical course of adjuvant treatment and survival. Reviewed

Toru Aoyama, Koji Oba, Michitaka Honda, Masaru Muto, Shuhei Mayanagi, Hiromichi Maeda, Mitsuro Kanda, Kosuke Kashiwabara, Junichi Sakamoto, Takaki Yoshikawa

International journal of clinical oncology Vol. 28 ( 6 ) page： 777 - 784 2023.6

Language：English Publishing type：Research paper (scientific journal)

AIM: We investigated whether or not postoperative complications (POCs) themselves have a negative survival impact or indirectly worsen the survival due to insufficient adjuvant chemotherapy in a pooled analysis of two large phase III studies performed in Japan PATIENTS AND METHODS: The study examined the patients who enrolled in 1304, phase III study comparing the efficacy of 6 and 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer patients and in 882, a phase III study to confirm the tolerability of oxaliplatin, fluorouracil, and l-leucovorin in Japanese stage II/III colon cancer patients. In our study, POCs were defined as the following major surgical complications: anastomotic leakage, pneumonia, bowel obstruction/ileus, surgical site infection, postoperative bleeding, urinary tract infection, and fistula. Patients were classified as those with POCs (C group) and those without POCs (NC group). RESULTS: A total of 2095 patients were examined in the present study. POCs were observed in 169 patients (8.1%). The overall survival (OS) rates at 5 years after surgery were 75.3% in the C group and 86.5% in the NC group (p = 0.0017). The hazard ratio of POCs for the OS in multivariate analysis was 1.70 (95% confidence interval, 1.19 to 2.45; p = 0.0040). The time to adjuvant treatment failure (TTF) of adjuvant chemotherapy was similar between the groups, being 68.6% in the C group and 67.1% in the NC group for the 6-month continuation rate of adjuvant chemotherapy. The dose reduction rate of adjuvant chemotherapy and adjuvant treatment suspension rate were also similar between the groups (C vs. NC groups: 45.0% vs. 48.7%, p = 0.3520; and 52.7% vs. 55.0%, p = 0.5522, respectively). CONCLUSION: POCs were associated with a poor prognosis but did not affect the intensity of adjuvant chemotherapy. These results suggested that POCs themselves negatively influence the survival.

DOI： 10.1007/s10147-023-02332-y

Web of Science

PubMed

Targeting Pancreatic Cancer with Novel Plumbagin Derivatives: Design, Synthesis, Molecular Mechanism, In Vitro and In Vivo Evaluation Reviewed

Awale Suresh, Baba Hayato, Phan Nguyen Duy, Kim Min Jo, Maneenet Juthamart, Sawaki Koichi, Kanda Mitsuro, Okumura Tomoyuki, Fujii Tsutomu, Okada Takuya, Maruyama Takahiro, Okada Takahiro, Toyooka Naoki

JOURNAL OF MEDICINAL CHEMISTRY Vol. 66 ( 12 ) page： 8054 - 8065 2023.5

　 PREV - NEXT 　

<KANDA Mitsuro>

Papers - KANDA Mitsuro